Nov 22, 2024 Gene therapies and regulatory milestone triggers: Licensors and Licensees beware By Ellen Lambrix Luca Cericola As briefly mentioned in our article last week on Priority Review Vouchers, the financial terms of a biopharma patent licence agreement...
Aug 19, 2024 CASGEVY: CRISPR/Cas9 gene therapy now available in England following NICE recommendation By Claire Smith Luca Cericola Vertex Pharmaceuticals announced a reimbursement agreement with NHS England for individuals 12 years or older with transfusion-dependent...
Jul 10, 2024 Challenges and opportunities for bio innovation: Views from the ON Helix 2024 conference By Adam Coughlin Luca Cericola Last week, Adam Coughlin and Luca Cericola from Bristows’ Commercial IP team attended ON Helix 2024, an annual conference hosted by One...
Jun 25, 2024 Biotech Review of the Year: Six months on By Bristows LLP It's hard to believe that six months have passed since we released the 11th edition of our Biotech Review of the Year publication. Our...
Jun 17, 2024 Licence Agreements for Cell and Gene Therapies By Claire Smith Ellen Lambrix Louisa Jacobs This article was first published in The Licensing Journal (Volume 44, Number 4). You can read and/or download it, in full, below: Cell...
Jun 13, 2024 Takeaways from the EU Pharma Law Forum 2024 By Jamie Hatzel Bristows was delighted to sponsor and attend this year’s EU Pharmaceutical Law Forum, which was held in Brussels at the Steigenberger...
Jun 11, 2024 Deal-making for cell and gene therapy companies: Insights from One Nucleus’ panel event By Claire Smith Luca Cericola Cell and gene therapies (CGTs) continue to hold considerable promise for the future of medicine, providing unprecedented therapeutic...
Jan 18, 2024 Strategic considerations for partnering with CDMOs for cell and gene therapies By Claire Smith Erik Müürsepp This article is part of our Biotech Review of the Year - Issue 11 publication The biopharmaceutical landscape is undergoing a steady but...
Jan 18, 2024 CRISPR technology in 2023 By Kate O'Sullivan This article is part of our Biotech Review of the Year - Issue 11 publication CRISPR technology has come on leaps and bounds in the last...
Jan 18, 2024 Publication: Biotech Review of the Year By Gregory Bacon Xisca Borrás Will Hewitt 2023 is likely to be remembered as a year in which a number of highly anticipated developments in the biotech industry finally came to...
Sep 18, 2023 First CRISPR therapy seeks regulatory approval, but will it be able to avoid the pitfalls of other cell and gene therapies? By Janna Lawrence Claire Smith Ellen Lambrix This article discusses the first CRISPR therapy seeks regulatory approval, raising the question but will it be able to avoid the pitfalls...
Jul 11, 2023 Curtain raised on New Genomic Techniques Regulation By Bristows European Commission proposes to ease the regulatory burden for gene-edited plants. But when will it become law, and in what form? The...